Tyr261

Site Information
sAsLGVGyRtQPMtA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 464148
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:	bone cancer ( 1 ) , osteosarcoma ( 1 ) , cervical cancer ( 4 ) , cervical adenocarcinoma ( 4 ) , leukemia ( 9 ) , acute myelogenous leukemia ( 9 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , non-small cell lung adenocarcinoma ( 5 ) , non-small cell squamous cell lung carcinoma ( 5 ) , lymphoma ( 3 , 7 , 8 ) , Hodgkin's lymphoma ( 3 , 7 , 8 )
Relevant cell line - cell type - tissue:	HeLa S3 (cervical) ( 4 ) , HUES-9 ('stem, embryonic') ( 2 ) , L540 (lymphoid) ( 3 , 7 , 8 ) , MKPL-1 (megakaryoblast) ( 6 , 9 ) , MNNG-HOS (bone cell) ( 1 ) , NCI-H1703 (squamous) ( 5 )

References
1	Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11 22461510 Curated Info
2	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
3	Gu TL, et al. (2010) Identification of activated Tnk1 kinase in Hodgkin's lymphoma. Leukemia 24, 861-5 20090780 Curated Info
4	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
5	Possemato A (2009) CST Curation Set: 8410; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
6	Gu TL, et al. (2007) A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 110, 323-33 17360941 Curated Info
7	Gu T (2006) CST Curation Set: 1936; Year: 2006; Biosample/Treatment: cell line, L540/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
8	Gu T (2006) CST Curation Set: 1627; Year: 2006; Biosample/Treatment: cell line, L540/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Gu T (2005) CST Curation Set: 716; Year: 2005; Biosample/Treatment: cell line, MKPL-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info